REPORT ID 1553

EMEA (Europe, Middle East and Africa) Checkpoint Inhibitors for Treating Cancer Market Report 2017

Publish Date
06-Dec-17
Pages
104
Format
Electronic (PDF)

In this report, the EMEA Checkpoint Inhibitors for Treating Cancer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Checkpoint Inhibitors for Treating Cancer for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Checkpoint Inhibitors for Treating Cancer market competition by top manufacturers/players, with Checkpoint Inhibitors for Treating Cancer sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Bristol-Myers Squibb(BMS)
    Merck
    Roche
    ...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    PD-1 inhibitors
    PD-L1 inhibitors
    CTLA-4 inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Melanoma Treatment
    Bladder Cancer Treatment
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Checkpoint Inhibitors for Treating Cancer Market Report 2017
1 Checkpoint Inhibitors for Treating Cancer Overview
    1.1 Product Overview and Scope of Checkpoint Inhibitors for Treating Cancer
    1.2 Classification of Checkpoint Inhibitors for Treating Cancer
        1.2.1 EMEA Checkpoint Inhibitors for Treating Cancer Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Checkpoint Inhibitors for Treating Cancer Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 PD-1 inhibitors
        1.2.4 PD-L1 inhibitors
        1.2.5 CTLA-4 inhibitors
    1.3 EMEA Checkpoint Inhibitors for Treating Cancer Market by Application/End Users
        1.3.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Melanoma Treatment
        1.3.3 Bladder Cancer Treatment
        1.3.4 Other
    1.4 EMEA Checkpoint Inhibitors for Treating Cancer Market by Region
        1.4.1 EMEA Checkpoint Inhibitors for Treating Cancer Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Checkpoint Inhibitors for Treating Cancer (2012-2022)
        1.5.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2022)

2 EMEA Checkpoint Inhibitors for Treating Cancer Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Checkpoint Inhibitors for Treating Cancer Market Competition by Players/Manufacturers
        2.1.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Checkpoint Inhibitors for Treating Cancer Sale Price by Players (2012-2017)
    2.2 EMEA Checkpoint Inhibitors for Treating Cancer (Volume and Value) by Type/Product Category
        2.2.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Checkpoint Inhibitors for Treating Cancer Sale Price by Type (2012-2017)
    2.3 EMEA Checkpoint Inhibitors for Treating Cancer (Volume) by Application
    2.4 EMEA Checkpoint Inhibitors for Treating Cancer (Volume and Value) by Region
        2.4.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Checkpoint Inhibitors for Treating Cancer Sales Price by Region (2012-2017)

3 Europe Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        3.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
    3.2 Europe Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type
    3.3 Europe Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Application
    3.4 Europe Checkpoint Inhibitors for Treating Cancer Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Volume by Countries (2012-2017)
        3.4.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2012-2017)
        3.4.3 Germany Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        3.4.4 France Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        3.4.5 UK Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        3.4.6 Russia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        3.4.7 Italy Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

4 Middle East Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        4.1.1 Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
    4.2 Middle East Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type
    4.3 Middle East Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Application
    4.4 Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        4.4.4 Israel Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        4.4.5 UAE Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        4.4.6 Iran Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

5 Africa Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        5.1.1 Africa Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
    5.2 Africa Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type
    5.3 Africa Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Application
    5.4 Africa Checkpoint Inhibitors for Treating Cancer Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Checkpoint Inhibitors for Treating Cancer Sales Volume by Countries (2012-2017)
        5.4.2 Africa Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2012-2017)
        5.4.3 South Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

6 EMEA Checkpoint Inhibitors for Treating Cancer Manufacturers/Players Profiles and Sales Data
    6.1 Bristol-Myers Squibb(BMS)
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Checkpoint Inhibitors for Treating Cancer Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Merck
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Checkpoint Inhibitors for Treating Cancer Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Roche
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Checkpoint Inhibitors for Treating Cancer Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    ...

7 Checkpoint Inhibitors for Treating Cancer Manufacturing Cost Analysis
    7.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Checkpoint Inhibitors for Treating Cancer Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Checkpoint Inhibitors for Treating Cancer Market Forecast (2017-2022)
    11.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Checkpoint Inhibitors for Treating Cancer Price and Trend Forecast (2017-2022)
    11.2 EMEA Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2017-2022)
    11.7 EMEA Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer